Recalled product relaunch boosts Sanofi Client Healthcare India Q1 gross sales; internet revenue jumps 36%
The relaunch of beforehand recalled merchandise helped Sanofi Client Healthcare India Restricted report a 15.5% enhance in home gross sales within the first quarter of FY26, as the corporate posted a 33% rise in income and a 36% bounce in internet revenue.
Income for the quarter stood at ₹229.2 crore, whereas revenue after tax (PAT) rose to ₹67.8 crore, in contrast with the year-ago interval. Export gross sales elevated 144% on a low base in the course of the quarter, the corporate stated.
The corporate had earlier introduced the relaunch of merchandise equivalent to DePURA 60K and Combiflam Suspension, which have been voluntarily recalled final yr.
Sanofi stated its home enterprise outpaced the market in the course of the quarter, delivering each market share beneficial properties and quantity progress. Exports additionally made a significant contribution to total efficiency.
Commenting on the outcomes, Himanshu Bakshi stated, “Our efficiency this quarter displays constant and disciplined execution throughout our key markets. The home enterprise outpaced the market, delivering each market share beneficial properties and quantity progress, whereas exports made a significant contribution to total outcomes.”
He added, “Guided by science and pushed by goal, we stay dedicated to simplifying self-care and making it extra accessible and efficient for customers.”
Sanofi Client Healthcare India grew to become an impartial entity following its demerger from Sanofi India Restricted in June 2024. The corporate operates within the shopper healthcare section with manufacturers together with Allegra, DePURA, Avil, and Combiflam.
